It has been shown that patients with HER2-positive BC have a significantly higher incidence of central nervous system (CNS) metastases after treatment with trastuzumab, probably secondary to improvements in systemic disease control and longer MOS associated with this pharmacological therapy [11]. Here, ERBB2 is linked to breast cancer.